Business, energy, technology, markets and global industry news from Business News Today

Taltz

PharmaDeviceNews Taltz
Representative image of an oral obesity treatment concept illustrating how Eli Lilly and Company’s Foundayo approval could widen access to GLP-1 weight loss therapy and reshape the next phase of the obesity drug market.
Pharma & Biotech

Eli Lilly’s TOGETHER-PsO trial links obesity treatment with psoriasis improvement

Eli Lilly's Taltz and Zepbound show broader immune and metabolic biomarker changes in psoriasis, building on Phase 3b skin clearance results.

Read More
Pharma & Biotech

Lilly’s Zepbound plus Taltz sustains stronger psoriasis and psoriatic arthritis outcomes at one year

Eli Lilly and Company says one-year Phase 3b data from TOGETHER-PsO and TOGETHER-PsA show sustained or deeper improvements when Zepbound and Taltz are used together in patients living with psoriatic disease and obesity.

Read More